Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

146.85
+2.621.82%
Post-market: 147.000.1500+0.10%16:28 EDT
Volume:4.96M
Turnover:729.75M
Market Cap:182.19B
PE:-56.16
High:148.60
Open:145.28
Low:144.85
Close:144.23
52wk High:157.29
52wk Low:112.82
Shares:1.24B
Float Shares:1.24B
Volume Ratio:1.00
T/O Rate:0.40%
Dividend:3.22
Dividend Rate:2.19%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.40
PE(LYR):21.66

Loading ...

$20 Billion In Deals And Counting: Lilly's CEO Targets The "White Space" Of Science For Larger M&A

Options & Short Sell
·
Sep 29

AstraZeneca To Invest $2 Billion In Summit And Co-Develop Drugs; Shares Jump After Hours

Options & Short Sell
·
Sep 29

Mirum's Liver Infection Drug Lowers Virus Levels in Late-Stage Study

Reuters
·
Sep 28

Xilio Therapeutics Names Yariv Houvras Chief Medical Officer

Reuters
·
Sep 28

Health Rounds: Genetic Discovery Yields Clues Toward Reversal of Alzheimer's Brain Damage

Reuters
·
Sep 25

Gilead Sciences Inc. Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 25

Moderna Inc. Stock Advances 7.0%, Outperforms Peers

Dow Jones
·
Sep 25

Pharmaceutical Stocks Jump. Moderna, Eli Lilly up over 3%; Novavax, Pfizer up Around 2%; Merck, Novo Nordisk up over 1%

Tiger Newspress
·
Sep 24

US Judge Steps Aside in Dispute over Hawaii Energy Settlement

Reuters
·
Sep 24

Stoke Therapeutics Names Solid Biosciences CEO Bo Cumbo to Board

Reuters
·
Sep 24

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 23

Moderna Inc. Stock Climbs 12.3%, Outperforms Peers

Dow Jones
·
Sep 22

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 18

Moderna Inc. Stock Climbs 8.5%, Outperforms Peers

Dow Jones
·
Sep 18

Gilead Chief Communications and Corporate Affairs Officer Johanna Mercier Sells USD 431,819 of Common Stock

Reuters
·
Sep 17

Gilead - Expands Six Royalty-Free Voluntary Licensing Agreements for Once-Yearly Lenacapavir for Hiv Prevention

THOMSON REUTERS
·
Sep 16

The 'CIA' Strategy Beating the Market: How One Top-Performing Money Manager Spots Mispriced Stocks.

Dow Jones
·
Sep 16

Rohto Starts Phase II Trial of RE-01 Cell Therapy for Refractory Ischemic Leg Ulcers

Reuters
·
Sep 16

Gilead Sciences Expands Lenacapavir Access to 14 Countries

MT Newswires Live
·
Sep 15

Gilead announces agreement with PAHO for lenacapavir access

TIPRANKS
·
Sep 15